drugset
drugset / Trial / NCT00563810

Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of MYO-029

NCT00563810 ↗

Phase 1 Completed 72 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedSingle-groupDouble-blindHealth-services research

Summary

This is a multiple dose study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of an investigational new drug.

Timeline

Start
2004-10
Primary completion
—
Completion
2006-04

Drugs

EvaluationDrugModalityDoseRoute
Subject STAMULUMAB Monoclonal antibody — Intravenous

Indications

No indication recorded.